Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CCXI

ChemoCentryx (CCXI) Stock Price, News & Analysis

ChemoCentryx logo

About ChemoCentryx Stock (NASDAQ:CCXI)

Advanced Chart

Key Stats

Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Stock News Headlines

Rishi Gupta's Net Worth
This Crypto Is Set to Explode in January
Free summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this means and how everyday investors like you can position themselves to potentially profit. The timing couldn't be more critical
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
See More Headlines

CCXI Stock Analysis - Frequently Asked Questions

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative net margin of 357.01% and a negative trailing twelve-month return on equity of 48.52%.

Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2021
Today
7/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CCXI
Employees
178
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.76 million
Net Margins
-357.01%
Pretax Margin
-357.01%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Price / Cash Flow
N/A
Book Value
$4.09 per share
Price / Book
12.71

Miscellaneous

Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:CCXI) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners